UCLB
UCLB is the wholly owned technology transfer and commercialisation company of University College London, monetising UCL research through IP licensing via its XIP portal and managing a portfolio of 95 active spinout companies.
- Company typePrivate
- Founded1993
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What UCLB does
UCL Business Ltd (UCLB) is the wholly owned technology transfer and commercialisation subsidiary of University College London, established to monetise UCL's research output through two primary mechanisms. First, it operates the XIP electronic licensing portal at xip.uclb.com, which hosts an online catalogue of UCL-developed intellectual property — spanning software (bioinformatics, materials modelling, AI tools, clinical data modelling), biological materials (cell lines, vectors, GMOs), healthcare tools (37 clinical outcome assessments), hardware (Engduino), media, and publications — and supports both academic and commercial licensing via automated approval workflows and tiered pricing. Second, UCLB creates, incubates, and holds equity in spinout companies formed from UCL research, currently overseeing 95 active spinouts that span life sciences, deep tech (including silicon quantum computing via Quantum Motion), and AI; these spinouts have collectively raised £3.06bn in external capital over the past five years and employ over 2,300 people.
UCLB's go-to-market is hybrid: a sales-led motion in which dedicated business managers are assigned per UCL department to guide researchers through commercialisation, complemented by a channel-led motion connecting UCL IP to global academic and commercial licensees via XIP (reaching 191+ countries). Revenue is generated through IP licensing royalties and spinout equity stakes. Its customer base is segmented across UCL researchers and academics (primary), other academic and research institutions licensing materials and software, and commercial companies in biotech, healthcare, software, and manufacturing. Operationally, UCLB is preparing a corporate identity refresh and new website launch scheduled for 29 June 2026.
Management depth is anchored by Director of BioPharm Richard Fagan, Investment Director Simon Goldman, Director David Dutton, and Associate Director (Physical Sciences & Engineering) Marina Santilli. UCLB holds Cyber Essentials certification, is a Living Wage Employer, and was awarded 'Best Performing New Company Creator' in 2025. It participates in broader UCL initiatives, most notably the €60M LIGAND-AI consortium for AI-driven drug discovery with 18 partners across nine countries.
UCLB firmographics
Firmographics- Name
- UCLB
- Legal name
- UCL Business Ltd
- Website
- https://uclb.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- UCLB is the wholly owned technology transfer and commercialisation company of University College London, monetising UCL research through IP licensing via its XIP portal and managing a portfolio of 95 active spinout companies.
- Ownership category
- akta.pro rank
UCLB industry classification
Industry- Product category
- Technology Transfer Services
- NAICS
- Colleges, Universities, and Professional Schools (611310), Scientific Research and Development Services (5417)
- SIC
- Patent Owners & Lessors (6794)
- akta.pro primary industry
- Research Administration & Compliance (Sponsored Programs, IRB/REB) (EDADAKAH)
Keywords
Where UCLB is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
UCLB business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- IP Licensing: UCLB generates revenue through licensing intellectual property developed at UCL to commercial entities. This includes software licenses, biological materials (cell lines, GMOs, vectors), healthcare tools, and other technologies available through the XIP portal. Licenses are offered for both academic (non-commercial research) and commercial purposes.
- Spinout Equity: UCLB creates and manages spinout companies from UCL research, holding equity stakes in portfolio companies that have collectively raised £3.06bn in external investment over five years.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Academic License - For non-commercial research use at academic institutions |
| One time/ perpetual license | Multi-year contract | Commercial License - For commercial entities and commercial use |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
UCLB product offering
Product offeringCore offering
UCLB commercializes research from University College London academics by licensing intellectual property (software, biological materials, healthcare tools, hardware, publications) through its XIP online portal and by creating and managing spinout companies. It generates revenue via IP licensing fees/royalties, spinout equity, and commercialization support services for UCL researchers across life sciences, deep tech, and AI sectors.
Product overview
UCLB operates as UCL Business Ltd, a wholly owned subsidiary of University College London, functioning as the technology transfer office that commercializes UCL research. The primary product is XIP, an IP licensing portal that enables online browsing and licensing of intellectual property including biological materials (GMOs, cell lines, vectors), healthcare tools (clinical outcome assessments), software (bioinformatics, AI tools, materials modelling), hardware, and publications. The platform supports academic and commercial licensing with automated approval workflows. Beyond XIP, UCLB provides spinout company support, funding access, and commercialization services for UCL researchers.
Differentiator
Problem solved
Functional benefit
Brands
- XIP: UCLB's IP licensing portal for online licensing of software and tangible materials developed at UCL.
Products and services
- XIP IP Licensing Portal UCLB's electronic IP licensing portal enabling online licensing of software and tangible materials developed at UCL via a single accessible platform with clear licensing terms and automated approval processes for academic and commercial users.
- Spinout Development & Management
Quantifiable outcome
- 95 active spinout companies collectively raised £3.06bn in external investment
- +3 more outcomes
Companies that use UCLB
Customer profileSegments3 records
Ideal customer profiles3 records
UCLB technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
UCLB partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, flagship and major.
- UCL (University College London)coreUCLB is a wholly owned subsidiary of University College London, serving as the university's dedicated technology transfer and commercialization company. UCL provides the research pipeline that UCLB commercializes through spinouts and licensing.
- Quantum MotionflagshipQuantum Motion is a spinout company from UCL and Oxford, pioneering CMOS-based quantum computing using standard silicon fabrication processes. UCLB holds interest in this spinout which delivered the industry's first full-stack silicon quantum computer to the UK National Quantum Computing Centre.
- UCL Spinout Companiesflagship95 active spinout companies including Unibuddy (raised £29M+), MotionInput Games, Quantum Motion (£42M Series B), and others across life sciences, deep tech, and AI sectors.
- LIGAND-AI ConsortiummajorUCL leads a €60 million global AI-driven drug discovery initiative called LIGAND-AI involving 18 partners across nine countries, with Pfizer and the Structural Genomics Consortium as key partners.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
UCLB competitors and assessment
Company assessmentDirect peers
- Edinburgh Research & Innovation (ERI): University of Edinburgh's commercialization arm, providing IP licensing, spinout support, and research services. Comparable UK Russell Group TTO with life-sciences and deep-tech deal flow.
- Imperial College Innovations: Imperial College London's technology transfer function commercializing research through spinouts and licensing. Comparable London-based TTO with strong STEM/healthcare focus similar to UCLB.
- Oxford University Innovation: Oxford's dedicated technology transfer and spinout creation company. Directly comparable to UCLB as a UK Russell Group TTO commercializing world-class research through licensing, equity, and spinout formation, with overlapping deep-tech and life-sciences deal flow.
- Cambridge Enterprise: University of Cambridge's technology transfer office handling licensing, spinouts, and equity. Closely comparable to UCLB given similar research intensity, deep-tech orientation, and global brand in university innovation.
- King's College London Ventures: King's College London's commercialization function focused on health and life sciences. Comparable London-based TTO with similar healthcare IP licensing and spinout activities.
- Manchester Innovation Factory / UoM Intellectual Property: University of Manchester's technology transfer arm handling spinouts and licensing across materials, life sciences, and engineering. Comparable UK Russell Group TTO.
Others
- Parkwalk Advisors: UK fund manager specializing in university spinout and technology IP investments. Comparable ecosystem participant that co-invests alongside TTOs like UCLB in UK university spinouts.
Broad incumbents
- MIT Technology Licensing Office (TLO): MIT's technology transfer office, one of the largest and most established globally. Comparable as a leading university TTO, though at significantly greater scale and with deeper commercialization infrastructure.
- Stanford Office of Technology Licensing (OTL): Stanford's technology licensing office handling IP from one of the world's most prolific university ecosystems. Comparable TTO operating model but at much larger scale and with deeper Silicon Valley network.
Regional players
- ETH transfer (Switzerland): ETH Zurich's technology transfer office, a leading European university TTO with deep tech and quantum spinouts. Comparable function and research profile but serves Swiss/European markets rather than the UK.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
UCLB social profiles
Digital presenceUCLB compliance and trust
Trust signalCompliance3 records
UCLB financial estimates
Financial estimateRevenue estimate
Valuation estimate
UCLB leadership team
Management profileNumber of profiles
Profiles4 records
UCLB subsidiaries and ownership
Company hierarchySubsidiaries1 record
UCLB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UCLB M&A and investment
M&A and investmentM&A
Investments41 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UCLB
What does UCLB do?
UCLB commercializes research from University College London academics by licensing intellectual property (software, biological materials, healthcare tools, hardware, publications) through its XIP online portal and by creating and managing spinout companies. It generates revenue via IP licensing fees/royalties, spinout equity, and commercialization support services for UCL researchers across life sciences, deep tech, and AI sectors.
Is UCLB a public or private company?
UCLB is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was UCLB founded?
UCLB was founded in 1993. It employs 51 to 100 people.
Where is UCLB based?
UCLB is headquartered in London, United Kingdom, in the Europe region.
How does UCLB make money?
Two revenue lines are on record. IP Licensing is the primary driver. The others are spinout Equity.
Who are UCLB's main competitors?
Direct peers on record are Edinburgh Research & Innovation (ERI), Imperial College Innovations, Oxford University Innovation, Cambridge Enterprise, King's College London Ventures and Manchester Innovation Factory / UoM Intellectual Property. Parkwalk Advisors is listed as an others. Broad incumbents are MIT Technology Licensing Office (TLO) and Stanford Office of Technology Licensing (OTL). ETH transfer (Switzerland) is listed as a regional player.
Does UCLB have an API?
No public API is recorded for UCLB.
What industry is UCLB in?
UCLB's product category is Technology Transfer Services. Its primary akta.pro industry code is EDADAKAH, Research Administration & Compliance (Sponsored Programs, IRB/REB). Its NAICS code is 611310 and its SIC code is 6794.